This efficacy was observed in melanoma cells carrying BRAF as well as N-Ras mutation, namely SK-MEL-28 and SK-MEL-2, suggesting that the ERK pathway is the point more crucial than the Akt pathway for the treatment with EVs (Amnio and Cesarean). Here, AKT1 is linked to melanoma.